All In Biotech

Drug Trial Radar · NCT00394277

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

Randomized, Multicenter, Double-blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response) and Safety of 360 μg Induction Dosing of Pegasys® in Combination With Higher Copegus® Doses in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater Than or Equal to 85 kg

Last checked: Nov 20, 2026Latest source record: Aug 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,175 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,175

Actual

Start

Feb 2007

Primary completion

Apr 2009

Study completion Apr 2009

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 31, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety of higher dose versus standard dose Copegus in combination with PEGASYS. Patients with chronic hepatitis C (CHC) genotype 1 infection of high viral titer, and baseline body weight ≥85 kg, will be randomized to one of 4 groups, to receive one of the following: a) PEGASYS 180 µg subcutaneously (sc) weekly plus Copegus 1200 mg orally (po) daily; b) PEGASYS 180 µg sc weekly plus Copegus 1400-1600 mg po daily; c)PEGASYS 360 µg sc weekly (induction) followed by 180 µg sc weekly (maintenance) plus Copegus 1200 mg po daily; or d) PEGASYS 360 µg sc weekly (induction) followed by 180 µg sc weekly (maintenance) plus Copegus 1400-1600 mg po daily. Following 48 weeks treatment, there will be a 24-week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

Conditions

  • Hepatitis C, Chronic

Interventions

  • peginterferon alfa-2aDrug

    180 µg sc weekly for 48 weeks

  • RibavirinDrug

    1200 mg po daily for 48 weeks

  • peginterferon alfa-2aDrug

    360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks

  • RibavirinDrug

    1400-1600 mg po daily for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)Time frame: Week 72

Locations

184 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    Phoenix, Arizona

  • Site not named

    Fresno, California

  • Site not named

    La Jolla, California

  • Site not named

    Lancaster, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Luis Obispo, California

  • Site not named

    San Marcos, California

  • Site not named

    Ventura, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Englewood, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami Beach, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Austell, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Winfield, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Des Moines, Iowa

  • Site not named

    Iowa City, Iowa

  • Site not named

    Iowa City, Iowa

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    New Orleans, Louisiana

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.